Trophoblast lineage specific expression of the alternative splicing factor RBFOX2 suggests a role in placental development.

Alternative splicing Cell fusion Epithelial to mesenchymal transition Extravillous trophoblast Placenta RBFOX2 Syncytiotrophoblast

Journal

Placenta
ISSN: 1532-3102
Titre abrégé: Placenta
Pays: Netherlands
ID NLM: 8006349

Informations de publication

Date de publication:
10 2020
Historique:
received: 16 02 2020
revised: 30 06 2020
accepted: 06 07 2020
pubmed: 9 8 2020
medline: 11 8 2021
entrez: 9 8 2020
Statut: ppublish

Résumé

RBFOX2, an RNA-binding protein, controls tissue-specific alternative splicing of exons in diverse processes of development. The progenitor cytotrophoblast of the human placenta differentiates into either the syncytiotrophoblast, formed via cell fusion, or the invasive extravillous trophoblast lineage. The placenta affords a singular system where a role for RBFOX2 in both cell invasion and cell fusion may be studied. We investigated a role for RBFOX2 in trophoblast cell differentiation, as a foundation for investigations of RBFOX2 in embryo implantation and placental development. Immunohistochemistry of RBFOX2 was performed on placental tissue sections from three trimesters of pregnancy and from pathological pregnancies. Primary trophoblast cell culture and immunofluorescence were employed to determine RBFOX2 expression upon cell fusion. Knockdown of RBFOX2 expression was performed with βhCG and syncytin-1 as molecular indicators of fusion. In both normal and pathological placentas, RBFOX2 expression was confined to the cytotrophoblast and the extravillous trophoblast, but absent from the syncytiotrophoblast. Additionally, we showed that primary trophoblasts that spontaneously fused in cell culture downregulated RBFOX2 expression. In functional experiments, knockdown expression of RBFOX2 significantly upregulated βhCG, while the upregulation of syncytin-1 did not reach statistical significance. RBFOX2, by conferring mRNA diversity, may act as a regulator switch in trophoblast differentiation to either the fusion or invasive pathways. By studying alternative splicing we further our understanding of placental development, yielding possible insights into preeclampsia, where expression of antiangiogenic isoforms produced through alternative splicing play a critical role in disease development and severity.

Identifiants

pubmed: 32762877
pii: S0143-4004(20)30194-6
doi: 10.1016/j.placenta.2020.07.004
pii:
doi:

Substances chimiques

RBFOX2 protein, human 0
RNA Splicing Factors 0
Repressor Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

142-149

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Auteurs

Debra Goldman-Wohl (D)

The Magda and Richard Hoffman Center for Human Placenta Research, Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Caryn Greenfield (C)

The Magda and Richard Hoffman Center for Human Placenta Research, Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Iris Eisenberg-Loebl (I)

The Magda and Richard Hoffman Center for Human Placenta Research, Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Polina Denichenko (P)

IMRIC Hadassah-Hebrew University School of Medicine, Jerusalem, Israel.

Amina Jbara (A)

IMRIC Hadassah-Hebrew University School of Medicine, Jerusalem, Israel.

Rotem Karni (R)

IMRIC Hadassah-Hebrew University School of Medicine, Jerusalem, Israel.

Ilana Ariel (I)

Department of Pathology Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Simcha Yagel (S)

The Magda and Richard Hoffman Center for Human Placenta Research, Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. Electronic address: simcha.yagel@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH